An interventional study of Decannulation with a medical device and Decannulation using surgical removal or manual compression in VA-ECMO, sponsored by IHF GmbH - Institut für Herzinfarktforschung. Recruiting at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by IHF GmbH - Institut für Herzinfarktforschung · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Background:
Patients with severe heart and lung failure may be treated with VA-ECMO (veno-arterial extracorporeal membrane oxygenation), a life-support machine that temporarily takes over the function of the heart and lungs. To connect the patient to ECMO, large tubes (cannulas) are inserted into major blood vessels in the groin area.
When the patient no longer needs ECMO, these cannulas must be removed - a process known as decannulation. Closing the artery after removing the cannula is a critical step and can be associated with complications such as bleeding, vessel injury, or blood clots.
Currently, there are different methods to close the artery:
There is no clear standard yet on which method is safest and most effective for ECMO patients.
Purpose of the Study:
The study aims to determine whether using a vascular closure device is as safe and effective as the current standard methods for femoral artery closure after VA-ECMO.
Study Design:
This is a randomized controlled trial. Patients who are scheduled for decannulation after VA-ECMO support will be randomly assigned to one of two groups:
Control Group: Patients receive standard care, which may be either:
This allows for a real-world comparison of the Closure Device method to current clinical practice.
IHF GmbH - Institut für Herzinfarktforschung is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Decannulation with a medical device
Procedure: Decannulation using surgical removal or manual compression
Wound Closure with a medical device
Wound closure using surgical removal or manual compression
Incidence of a combined vessel-orientated clinical endpoint (VOCE)
Time frame: within 48 hours post ECMO removal
Length of ICU (intensive care unit) stay post ECMO removal
Time frame: Prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first
Length of hospital stay post ECMO removal
Time frame: Prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first
Time to mobilization post ECMO removal
Time frame: Prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first
Costs of hospital stay
Time frame: Prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first
Incidence of Bleeding requiring transfusion (BARC3a)
Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first
Vascular complication requiring surgical or interventional therapy
Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first
Wound infection requiring antibiotic use or surgical debridement
Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first
Rate of pseudoaneurysms as detected by vascular Ultrasound
Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first
Rate of veinous thrombosis in the lower vessels as detected by vascular ultrasound
Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first
Rate of arterial thrombosis in the lower vessel as detected by vascular ultrasound
Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first
Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IHF GmbH - Institut für Herzinfarktforschung